Retinitis Pigmentosa Therapeutics - Pipeline Review 2017

1
Drug Candidates in Retinitis Pigmentosa
Therapeutics Pipeline to Develop More as Gene
Therapy
2
Retinitis Pigmentosa Therapeutics
Retinitis Pigmentosa therapeutics pipeline in 2017
Retinitis pigmentosa, also known as retinitis, is
a degenerative eye disease that occurs due to the
progressive degeneration of the rod photoreceptor
cells in the retina of eye. The study analyzed
that the retinitis pigmentosa therapeutics
pipeline comprises approximately 38 drug
candidates in different stages of
development. Access Report Summary with Detailed
TOC on Retinitis Pigmentosa Therapeutics
Pipeline Analysis, 2017 - Clinical Trials
Results, Patents, Designations, Collaborations,
and Other Developments at https//www.psmarketre
search.com/market-analysis/retinitis-pigmentosa-th
erapeutics-pipeline-analysis
3
Retinitis Pigmentosa Therapeutics
Insights on market segments
Orphan drug designations from the regulatory
bodies such as Food and Drug Administration
(FDA), European Medicines Agency (EMA) and
Ministry of Health, Labour and Welfare (MHLW) is
a key driver for the development of pipeline
drugs, for treating retinitis pigmentosa.
Majority of the pipeline drug candidates are
being developed using the intravitreal route of
administration. HORAMA S.A. is in the process of
developing two phase I/II, and one Pre-Clinical
therapeutics for the treatment of retinitis
pigmentosa.
4
Retinitis Pigmentosa Therapeutics
Maximum drugs being developed as gene therapy
Many companies are increasingly emphasizing on
the development of gene therapy candidates, due
to their positive clinical results in the
treatment of retinitis pigmentosa. Based on
molecule type, around 50.0 of the drug
candidates in the retinitis pigmentosa pipeline
are expected to be developed based on gene
therapy.
5
Retinitis Pigmentosa Therapeutics
Technological advancements spurring the growth of
the retinitis pigmentosa therapeutics pipeline
Technological advancements are spurring the
pipeline growth, for instance, AAV vector
manufacturing platform was used in the
development of AGTC-501 by the Applied Genetic
Technologies Corp for the treatment of retinitis
pigmentosa Some of the key players developing
drugs for the treatment of retinitis pigmentosa
include jCyte, Inc., Dompe Farmaceutici SpA,
ProRetina Therapeutics, S.L., and Recursion
Pharmaceuticals Inc.
6
Retinitis Pigmentosa Therapeutics
Download report sample at
https//www.psmarketresearch.com/market-analysis/r
etinitis-pigmentosa-therapeutics-pipeline-analysis
/report-sample
7
GET IN TOUCH
THANK YOU!
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886